Abstract:Abstract Abstract 4677 Introdution The expression of CD56 antigen and over-expression of the multidrug resistance gene 1 (MDR1) seems to confer the poor therapeutic outcome to AML. The aim of this study is to investigate the relationship between CD56 antigen expression and MDR1 gene expression in patients with de novo AML and explore the indicating effect of these two factors on clinical drug resistance. Patients and methods A real-time quantitative reverse transcriptase polymerase chain reaction method was established for detecting MDR1 expression levels and a three-color flow cytometry analysis with CD45/SSC gating was used to examine CD56 antigen expression in 79 patients with de novo AML. Results CD56 antigen was recorded in 19 out of 79 cases (24.1%) and particularly in those with M5 subtype and t(8;21) AML. Moreover, CD56 expression was significantly associated with unfavorable cytogenetic abnormalities (P< 0.05). Significantly higher percentage (57.1%, 4/7) of patients with t(8;21) demonstrated CD56 expression than those with favorable cytogenetic abnormalities (P< 0.05). CD56+ AML patients had higher incidence of splenohepatomegalia and level of lactate dehydrogenase than CD56- patients (P< 0.05). The median expression level of MDR1 was statistically higher in CD56+ AML patients than that in CD56- cases (P< 0.001) and 89.5% (17/19) CD56+ AML patients were found with high MDR1 expression. The CR rate in high MDR1 / CD56+ AML patients was significantly lower than that in low MDR1/ CD56- cases. (58.8% vs 89.2%, P< 0.01). Conclusions There is a linear correlation between MDR1 and CD56 expression in AML. This relationship may explain why CD56 expression is related to a poor prognosis in AML. Therefore both with high MDR1 expression level and CD56 antigen expression can identify AML patients with unfavorable outcome. Disclosures: No relevant conflicts of interest to declare.

Relationship of anti-apoptosis gene bcl-xL and multidrug resistance in leukemia cells

Role of Bcl-2-related anti-apoptosis mechanism in drug resistance of leukemia

Expression of BCL2L12 gene in de novo acute myeloid leukemia and its clinical implications]

Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis

Expression of Bcl-2, Bcl-XL, Bax and Bak in acute leukemia cells and its clinical significance

The Clinical Significance of BCL-2 Gene Expression in Acute Leukemia

BCL11A and MDR1 expressions have prognostic impact in patients with acute myeloid leukemia treated with chemotherapy.

Prognostic Significance of Bcl-Xl Gene Expression and Apoptotic Cell Counts in Follicular Lymphoma.

Over expression of bcl-2 resulting in resistance todaunorubicin in acute myeloid leukemia cells

Expression of Caspase-3 and Bcl-2 in leukaemia cell apoptosis and its significance in multiple-drug resistance

Relationship Between Expression of Apoptosis-modulating Proteins and Multidrug Resistance in K562/VCR Cells

Relationship between ectopic expression of multidrug resistance-related proteins and clinical efficacy and prognosis in acute leukemia

Expression of Bcl-2 and P170 in acute myelocytic leukemia and clinical significance

Transcript-Level Dysregulation of BCL2 Family Genes in Acute Myeloblastic Leukemia

Inhibition of Bcl-xL Overcomes Polyploidy Resistance and Leads to Apoptotic Cell Death in Acute Myeloid Leukemia Cells

Significance of quantification of MDR1 gene and CD56 antigen expression in acute myeloid leukemia patients

Relationship Between Expression of Cell Regulatory Factor SKP2 and Drug Resistance of HL-60/A Cells

The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients

[BCL-XL Expression and Mutation in Non-Hodgkin's Lymphoma].

Relationship Between CD56 Antigen Expression and Quantification of MDR1 Gene Expression in Patients with De Novo Acute Myeloid Leukemia(AML).

Simultaneous targeting of MCL1 and ABCB1 as a novel strategy to overcome drug resistance in human leukaemia